We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.46B
AUM Growth
-$440K
Cap. Flow
-$163M
Cap. Flow %
-11.2%
Top 10 Hldgs %
60.09%
Holding
84
New
10
Increased
23
Reduced
32
Closed
17
Avg Time Held Equity + Options
1.7 years
Top 10 Avg Time Held Equity + Options
1.2 years
Top 20 Avg Time Held Equity + Options
1.3 years
Avg Time Held Equity only
1.7 years
Top 10 Avg Time Held Equity only
1.2 years
Top 20 Avg Time Held Equity only
1.4 years

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$24.1M
2
ZIMV icon
ZimVie
ZIMV
+$23.4M
3
FTRE icon
Fortrea Holdings
FTRE
+$10.8M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$10.2M
5
BHC icon
Bausch Health
BHC
+$10.1M

Top Sells

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$44.6M
2
UTHR icon
United Therapeutics
UTHR
+$35.3M
3
NTRA icon
Natera
NTRA
+$34.8M
4
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$26M
5
NVO icon
Novo Nordisk
NVO
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 89.3%
2 Miscellaneous 10.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
HUM icon
26
Humana
HUM
$49.6B
$10.7M 0.73%
33,860
-4,163
-11% -$1.48M
2022 Q2
9 quarters
DHR icon
27
Danaher
DHR
$161B
$10.7M 0.73%
38,429
-2,426
-6% -$642K
2018 Q3
24 quarters
CNC icon
28
Centene
CNC
$34.2B
$10.2M 0.7%
134,959
+19,139
+17% +$1.4M
2021 Q1
14 quarters
ELV icon
29
Elevance Health
ELV
$92.9B
$10.1M 0.69%
19,465
+4,808
+33% +$2.57M
2020 Q4
15 quarters
FTRE icon
30
Fortrea Holdings
FTRE
$2.14B
$9.16M 0.63%
+457,967
New +$10.8M
2024 Q3
0 quarters
ITCI icon
31
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.11M 0.62%
+124,491
New +$9.36M
2024 Q3
0 quarters
EOLS icon
32
Evolus
EOLS
$469M
$7.34M 0.5%
453,061
-121,401
-21% -$1.7M
2024 Q2
1 quarter
BHVN icon
33
Biohaven
BHVN
$1.63B
$6.62M 0.45%
+132,537
New +$5.16M
2024 Q3
0 quarters
ARQT icon
34
Arcutis Biotherapeutics
ARQT
$3.62B
$6.45M 0.44%
693,263
-144,584
-17% -$1.43M
2024 Q2
1 quarter
STRO icon
35
Sutro Biopharma
STRO
$181M
$6.37M 0.44%
184,199
+10,286
+6% +$403K
2023 Q2
5 quarters
BKD icon
36
Brookdale Senior Living
BKD
$2.41B
$5.85M 0.4%
861,268
-685,574
-44% -$4.89M
2024 Q1
2 quarters
NAMS icon
37
NewAmsterdam Pharma
NAMS
$2.37B
$5.1M 0.35%
307,357
-22,533
-7% -$390K
2023 Q1
6 quarters
FNA icon
38
DELISTED
Paragon 28, Inc.
FNA
$5M 0.34%
+749,213
New +$5.67M
2024 Q3
0 quarters
GOSS icon
39
Gossamer Bio
GOSS
$53.6M
$4.91M 0.34%
62,231
-6,321
-9% -$486K
2021 Q3
12 quarters
TSVT icon
40
DELISTED
2seventy bio
TSVT
$4.71M 0.32%
998,079
-109,664
-10% -$495K
2023 Q3
4 quarters
KPTI icon
41
Karyopharm Therapeutics
KPTI
$8.85M
$4.6M 0.32%
369,859
+37,380
+11% +$465K
2024 Q1
2 quarters
AVTR icon
42
Avantor
AVTR
$11.1B
$4.36M 0.3%
168,369
+42,975
+34% +$1.05M
2023 Q3
4 quarters
BCRX icon
43
BioCryst Pharmaceuticals
BCRX
$1.99B
$4.07M 0.28%
535,405
-617,168
-54% -$4.69M
2022 Q4
7 quarters
ICLR icon
44
Icon
ICLR
$13.1B
$3.93M 0.27%
13,668
+1,026
+8% +$324K
2021 Q3
12 quarters
KURA icon
45
Kura Oncology
KURA
$808M
$3.76M 0.26%
192,398
+120,081
+166% +$2.43M
2024 Q2
1 quarter
MOH icon
46
Molina Healthcare
MOH
$10.8B
$3.65M 0.25%
10,588
-7,689
-42% -$2.54M
2023 Q2
5 quarters
MRUS icon
47
DELISTED
Merus
MRUS
$3.41M 0.23%
68,258
+1,784
+3% +$93.1K
2021 Q4
11 quarters
STAA icon
48
STAAR Surgical
STAA
$1.07B
$3.39M 0.23%
+91,199
New +$3.4M
2024 Q3
0 quarters
PBYI icon
49
Puma Biotechnology
PBYI
$507M
$3.3M 0.23%
1,293,257
-35,197
-3% -$107K
2021 Q3
12 quarters
ZLAB icon
50
Zai Lab
ZLAB
$2.6B
$3.26M 0.22%
+135,219
New +$2.56M
2024 Q3
0 quarters
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q3 2024 Portfolio in Review

As of Q3 2024, Eversept Partners held 84 positions worth $1.46B, down 0.03% from $1.46B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Eversept Partners withdrew a net $163M in Q3 2024, closing 17 positions and reducing 32 holdings. Its most notable exit was Novo Nordisk, an estimated $21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 89% a quarter earlier, followed by Miscellaneous.

Against the trend, Eversept Partners opened a new position in Fortrea Holdings worth $9.16M.

  • Eversept Partners's largest Q3 2024 buy was Fortrea Holdings: 457,967 shares worth $9.16M.
  • Eversept Partners added most to GSK in Q3 2024, an estimated $24.1M increase.
  • Eversept Partners's biggest Q3 2024 reduction was Inspire Medical Systems, cutting an estimated $44.6M.
  • Eversept Partners fully exited Novo Nordisk in Q3 2024, selling an estimated $21M.
  • Eversept Partners's ten largest holdings make up 60% of its $1.46B portfolio in Q3 2024.
  • Eversept Partners opened 10 new positions and closed 17 in Q3 2024.
  • Eversept Partners's portfolio value fell 0.03% quarter-over-quarter to $1.46B.

Based on Eversept Partners's 13F filing for Q3 2024, filed 14 Nov 2024.